US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apogee Therapeutics

35.61

-1.7500-4.68%

Post-market: 35.25-0.3600-1.01%16:32 EDT

Volume:664.86K

Turnover:24.04M

Market Cap:2.07B

PE:-10.79

High:37.87

Open:37.01

Low:35.24

Close:37.36

Loading ...

Overview Company News Filings

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee (APOG) Stock Trades Down, Here Is Why

This Apogee Therapeutics Insider Increased Their Holding In The Last Year

Simply Wall St.

Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025

THOMSON REUTERS

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions

THOMSON REUTERS

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

TD Cowen Sticks to Its Buy Rating for Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Price Target Raised to $110.00/Share From $95.00 by Guggenheim

Apogee Therapeutics Advances in I&I Disease Treatments

Apogee Therapeutics Inc : Jefferies Raises Target Price to $82 From $75

THOMSON REUTERS

Wedbush Adjusts Price Target on Apogee Therapeutics to $90 From $87, Maintains Outperform Rating

MT Newswires Live

Apogee Therapeutics Inc : Wedbush Raises Target Price to $90 From $87

THOMSON REUTERS

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Apogee Therapeutics Announces Agenda for Virtual R&D Day

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/APGE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"APGE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APGE\",,,,,undefined,":{"symbol":"APGE","market":"US","secType":"STK","nameCN":"Apogee Therapeutics","latestPrice":35.61,"timestamp":1743537600000,"preClose":37.36,"halted":0,"volume":664857,"hourTrading":{"tag":"盘后","latestPrice":35.25,"preClose":35.61,"latestTime":"16:32 EDT","volume":775,"amount":27544.848499999996,"timestamp":1743539577616},"delay":0,"floatShares":39037712,"shares":58087357,"eps":-3.300106,"marketStatus":"Post-Market Trading","change":-1.75,"latestTime":"04-01 17:17:27 EDT","open":37.01,"high":37.87,"low":35.24,"amount":24040054.982538,"amplitude":0.070396,"askPrice":38,"askSize":100,"bidPrice":35,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-3.300106,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743552000000},"marketStatusCode":4,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":37.36,"preHourTrading":{"tag":"盘前","latestPrice":37.35,"preClose":37.36,"latestTime":"09:28 EDT","volume":2109,"amount":78779.24855999999,"timestamp":1743514095068},"postHourTrading":{"tag":"盘后","latestPrice":35.25,"preClose":35.61,"latestTime":"16:32 EDT","volume":775,"amount":27544.848499999996,"timestamp":1743539577616},"volumeRatio":0.894613,"impliedVol":0.2976,"impliedVolPercentile":0.0199},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APGE\",,,,,undefined,":{"symbol":"APGE","floatShares":39037712,"roa":"-23.46%","roe":"-33.22%","lyrEps":-3.300106,"volumeRatio":0.894613,"shares":58087357,"dividePrice":0,"high":37.87,"amplitude":0.070396,"preClose":37.36,"low":35.24,"week52Low":29.1,"pbRate":"2.89","week52High":68.21,"institutionHeld":0,"latestPrice":35.61,"committee":0.333333,"eps":-3.300106,"divideRate":0,"volume":664857,"delay":0,"ttmEps":-3.300106,"open":37.01,"prevYearClose":45.3,"prevWeekClose":39.72,"prevMonthClose":37.36,"prevQuarterClose":37.36,"fiveDayClose":39.89,"twentyDayClose":30.37,"sixtyDayClose":47.15},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APGE\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508114773","title":"Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114773","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114773?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":"Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled. Part A 16-week proof-of-concept data anticipated in mid-2025. APEX is a Phase 2 randomized, placebo-controlled clinical trial evaluating APG777, a novel, subcutaneous  extended half-life monoclonal antibody  targeting IL-13 – a critical cytokine in inflammation and a primary driver of AD, in patients with moderate-to-severe AD. The trial was designed to combine the typical Phase 2a and 2b portions of a clinical trial into a single protocol. Part A exceeded expected enrollment with 123 patients randomized 2:1 to APG777 versus placebo; patients assigned to APG777 received induction regimen dosing of 720mg at weeks 0 and 2, followed by 360mg at weeks 4 and 12 and the trial has greater than 90% power for the primary endpoint. Patients benefiting from treatment will continue to APG777 maintenance dosing, which will evaluate 3- or 6-month dosing. Part B is a placebo-controlled dose opt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-therapeutics-announces-first-patient-120000106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2507145608","title":"Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507145608","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507145608?lang=en_us&edition=fundamental","pubTime":"2025-01-31 04:44","pubTimestamp":1738269876,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Stocks That Will Double in 2025.In this article, we are going to take a look at where Apogee Therapeutics, Inc.  stands against the other stocks.The Fed's Probable Path and its Impact on Earnings. A lot is happening in the market, especially within the growth sectors. The launch of DeepSeek has caused significant uproar across the tech market in the United States, and with key names reporting earnings this week, investors are uncertain about how the market is going to play out in 2025. On top of that, the question mark on the Fed's future actions poses yet another blow to investor sentiment. On January 30, Jim Bullard, former St. Louis Fed president, joined Market Domination on Yahoo Finance to discuss his market thesis amid the Fed's decisions to keep rates steady.Speaking of the Fed's meeting, Kaiser suggested that the updated economic data has been in line wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-apogee-therapeutics-inc-apge-204436292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","US12M.BOND","US7Y.BOND","USJW.SI","NVIW.SI","NQmain","US30Y.BOND","MNQmain","US5Y.BOND","TQQQ","USAW.SI","APGE","TSYW.SI","US10Y.BOND","US2Y.BOND","BK4139","QQQ","QID","QLD","US3Y.BOND","SQQQ",".IXIC","US6M.BOND"],"gpt_icon":1},{"id":"2507662680","title":"Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507662680","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507662680?lang=en_us&edition=fundamental","pubTime":"2025-01-29 20:30","pubTimestamp":1738153800,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO and BOSTON, Jan.  29, 2025  (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenhei","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017070/0/en/Apogee-Therapeutics-to-Participate-at-the-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4011","APGE","SMID"],"gpt_icon":0},{"id":"2501733712","title":"Apogee (APOG) Stock Trades Down, Here Is Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2501733712","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501733712?lang=en_us&edition=fundamental","pubTime":"2025-01-08 01:11","pubTimestamp":1736269877,"startTime":"0","endTime":"0","summary":"Shares of architectural products company Apogee  fell 17% in the morning session after the company reported underwhelming calendar fourth-quarter 2024 results. Sales were flat year on year, and this weighed on profits as operating margin fell. In addition, its full-year EPS guidance slightly missed, suggesting the weakness might be more pronounced in the coming quarters. Overall, we think this was a challenging quarter.Apogee is down 16.9% since the beginning of the year, and at $59.22 per share, it is trading 32.1% below its 52-week high of $87.22 from November 2024. Investors who bought $1,000 worth of Apogee’s shares 5 years ago would now be looking at an investment worth $1,814.Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft  to Alphabet , Coca-Cola  to Monster Beverage  could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively unde","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-apog-stock-trades-down-171117308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1564329628.SGD","LU1935042991.SGD","APGE","BK4576","LU2552382215.SGD","IE00BGHQF631.EUR","LU1691799644.USD","APOG","IE00B3S45H60.SGD","LU2023251221.USD","LU2362541273.HKD","SG9999015341.SGD","LU2191332357.HKD","LU2063271972.USD","LU0494093205.USD","SG9999014542.SGD","SG9999015945.SGD","BK4579","IE0009356076.USD","IE00BYQQ9H92.USD","IE00BDGV0183.EUR","LU1989773731.SGD","LU0957791311.USD","LU2237443465.HKD","SG9999014914.USD","LU1066051811.HKD","LU0128525929.USD","LU0724617625.USD","MNST","LU1267930730.SGD","LU1861127337.USD","LU0094547139.USD","LU1316542783.SGD","LU1712237335.SGD","LU1116320737.USD","IE0034235188.USD","LU2491050071.SGD","LU1043141123.HKD","LU1301847155.USD","LU0784385170.HKD","LU0345774631.USD","IE00B42XCP33.USD","IE00BFXG0V08.USD","USJW.SI","IE00B1BXHZ80.USD","IE00BSNM7G36.USD"],"gpt_icon":1},{"id":"2494044556","title":"This Apogee Therapeutics Insider Increased Their Holding In The Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2494044556","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494044556?lang=en_us&edition=fundamental","pubTime":"2024-12-25 19:33","pubTimestamp":1735126413,"startTime":"0","endTime":"0","summary":"Looking at Apogee Therapeutics, Inc.'s  insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.Check out our latest analysis for Apogee Therapeutics. The Last 12 Months Of Insider Transactions At Apogee Therapeutics. It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Apogee Therapeutics we think they are probably pretty confident of a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-therapeutics-insider-increased-holding-113333040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2490094398","title":"Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2490094398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490094398?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA1D7MTM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2490091044","title":"Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2490091044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490091044?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA1D7MTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2490094414","title":"Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2490094414","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490094414?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832000,"startTime":"0","endTime":"0","summary":"Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus mon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/10/2994371/0/en/Apogee-Therapeutics-Announces-First-Participants-Dosed-in-Phase-1-Clinical-Trial-of-APG333-its-Novel-Half-Life-Extended-TSLP-Antibody-for-the-Treatment-of-Respiratory-and-Broader-I.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","LU1861558580.USD","BK4551","IE00BHPRN162.USD","IE00B19Z3581.USD","LU1861559042.SGD","PK","BK4218","BK4139","BK4581","BK4554","BK4588","BK4106","IE0002270589.USD","BK4227","TSLP","IE00B7SZLL34.SGD","BK4585","APGE","BK4503","IE00B19Z3B42.SGD","BK4528"],"gpt_icon":0},{"id":"2489635294","title":"TD Cowen Sticks to Its Buy Rating for Apogee Therapeutics, Inc. (APGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489635294","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489635294?lang=en_us&edition=fundamental","pubTime":"2024-12-05 23:17","pubTimestamp":1733411834,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report) on December 3. The company’s shares ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-apogee-therapeutics-inc-apge?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-apogee-therapeutics-inc-apge?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","COWN","APGE"],"gpt_icon":0},{"id":"2488928940","title":"Apogee Therapeutics Price Target Raised to $110.00/Share From $95.00 by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2488928940","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488928940?lang=en_us&edition=fundamental","pubTime":"2024-12-04 00:42","pubTimestamp":1733244120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APGE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2024 11:42 ET (16:42 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE"],"gpt_icon":0},{"id":"2488150739","title":"Apogee Therapeutics Advances in I&I Disease Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2488150739","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488150739?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:52","pubTimestamp":1733226763,"startTime":"0","endTime":"0","summary":"Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Apogee Therapeutics is making significant strides in its biologic programs for inflammatory and immunology (I&I) diseases. The company is showcasing promising data from its APG808 and APG777 trials, indicating potential for less frequent dosing and enhanced treatment efficacy. APG777, in particular, shows potential for annual dosing in atopic dermatitis, a vast market opportunity. Furthermore, the company is advancing combination therapies to improve outcomes in conditions like asthma and COPD, positioning itself as a disruptive force in the I&I treatment landscape.For a thorough assessment of APGE stock, go to TipRanks’ Stock Analysis page.OSCV, RBNK: 2 ETFs with Upside Potential and Steady Dividends. Upcoming Stock Splits This Week  – Stay Invested. SpaceX Rival Rocket Lab USA’s Stock Soars to New Highs","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lBatGXdmW601L3jZUeEVwQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/e1839507ce9d5542b9a5313ac8d70b9e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lBatGXdmW601L3jZUeEVwQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/e1839507ce9d5542b9a5313ac8d70b9e"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/apogee-therapeutics-advances-disease-treatments-115243354.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-therapeutics-advances-disease-treatments-115243354.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2488896698","title":"Apogee Therapeutics Inc :  Jefferies Raises Target Price to $82 From $75","url":"https://stock-news.laohu8.com/highlight/detail?id=2488896698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488896698?lang=en_us&edition=fundamental","pubTime":"2024-12-03 15:16","pubTimestamp":1733210164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nFWN3N4028:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2488678252","title":"Wedbush Adjusts Price Target on Apogee Therapeutics to $90 From $87, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2488678252","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488678252?lang=en_us&edition=fundamental","pubTime":"2024-12-02 20:00","pubTimestamp":1733140854,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics (APGE) has an average rating of buy and mean price target of $92.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APGE"],"gpt_icon":0},{"id":"2488767869","title":"Apogee Therapeutics Inc : Wedbush Raises Target Price to $90 From $87","url":"https://stock-news.laohu8.com/highlight/detail?id=2488767869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488767869?lang=en_us&edition=fundamental","pubTime":"2024-12-02 19:56","pubTimestamp":1733140590,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nFWN3N30LD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2488275536","title":"Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2488275536","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488275536?lang=en_us&edition=fundamental","pubTime":"2024-12-02 19:00","pubTimestamp":1733137200,"startTime":"0","endTime":"0","summary":"Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/02/2989580/0/en/Apogee-Therapeutics-Highlights-Progress-and-Best-in-Class-Potential-of-Novel-Biologic-Programs-for-I-I-Diseases-at-2024-Inaugural-R-D-Day.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BHPRN162.USD","BK4023","BK4097","BK4551","LU1169590202.USD","LU1861559042.SGD","BK4585","LU1169589451.USD","BK4528","BK4588","IE0002270589.USD","APGE","LU2065732104.USD","BK4503","BK4227","LU1861558580.USD","IE00B7SZLL34.SGD","BK4581","PD","BK4106","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4139","BK4554","PRGS"],"gpt_icon":0},{"id":"2487981605","title":"Apogee Therapeutics Announces Agenda for Virtual R&D Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2487981605","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487981605?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:00","pubTimestamp":1732903200,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO and WALTHAM, Mass., Nov.  29, 2024  (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for dif","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/29/2989252/0/en/Apogee-Therapeutics-Announces-Agenda-for-Virtual-R-D-Day.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APGE","KOL"],"gpt_icon":0}],"pageSize":16,"totalPage":5,"pageCount":3,"totalSize":72}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APGE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-03","symbol":"APGE","fiscalQuarterEnding":"2024/12","expectedEps":-0.94,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-1.19},{"market":"US","date":"2024-11-12","symbol":"APGE","fiscalQuarterEnding":"2024/09","expectedEps":-0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APGE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APGE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.75,"buy":0.25,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.75,"analysts":8,"updateTime":1732766400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APGE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APGE","date":"2025-03-31","current":-12.666926,"percent":0.931034,"low":-42.099968,"twenty":-27.097365,"median":-21.77128,"eighty":-15.338586,"high":-9.685159,"avg":-22.094154,"sd":7.502835,"marketCap":2307229820},"quantilePoints":[{"date":"2023-07-14","current":-14.120082,"twenty":-14.120082,"median":-14.120082,"eighty":-14.120082,"marketCap":728904256},{"date":"2023-07-21","current":-18.011929,"twenty":-18.356106,"median":-18.157543,"eighty":-18.011929,"marketCap":929808491},{"date":"2023-07-28","current":-20.899222,"twenty":-20.280785,"median":-18.735584,"eighty":-18.04723,"marketCap":1078855761},{"date":"2023-08-04","current":-20.732342,"twenty":-20.732342,"median":-20.114656,"eighty":-18.267856,"marketCap":1070241131},{"date":"2023-08-11","current":-21.547107,"twenty":-20.865853,"median":-20.262175,"eighty":-18.356106,"marketCap":1112300797},{"date":"2023-08-18","current":-23.166822,"twenty":-21.272247,"median":-20.482022,"eighty":-18.735584,"marketCap":1195913385},{"date":"2023-08-25","current":-24.246631,"twenty":-22.764347,"median":-20.836643,"eighty":-19.947026,"marketCap":1251655111},{"date":"2023-09-01","current":-16.923199,"twenty":-22.901778,"median":-20.784492,"eighty":-18.356106,"marketCap":1162468350},{"date":"2023-09-08","current":-17.424846,"twenty":-22.791833,"median":-20.482022,"eighty":-18.04017,"marketCap":1196926871},{"date":"2023-09-15","current":-15.33711,"twenty":-22.261745,"median":-20.262175,"eighty":-17.454355,"marketCap":1053518613},{"date":"2023-09-22","current":-15.742854,"twenty":-21.87694,"median":-20.07464,"eighty":-16.946806,"marketCap":1081389476},{"date":"2023-09-29","current":-15.255962,"twenty":-21.600116,"median":-18.735584,"eighty":-16.181057,"marketCap":1047944441},{"date":"2023-10-06","current":-15.816626,"twenty":-21.327219,"median":-18.248406,"eighty":-15.736952,"marketCap":1086456906},{"date":"2023-10-13","current":-14.754315,"twenty":-21.232981,"median":-18.011929,"eighty":-15.43744,"marketCap":1013485920},{"date":"2023-10-20","current":-14.732183,"twenty":-21.097514,"median":-17.509684,"eighty":-15.343012,"marketCap":1011965691},{"date":"2023-10-27","current":-11.065736,"twenty":-21.032725,"median":-17.443289,"eighty":-15.295798,"marketCap":760114440},{"date":"2023-11-03","current":-13.714136,"twenty":-20.892548,"median":-17.107628,"eighty":-15.064155,"marketCap":942035162},{"date":"2023-11-10","current":-11.751812,"twenty":-20.860011,"median":-16.901067,"eighty":-14.764643,"marketCap":807241535},{"date":"2023-11-17","current":-12.191046,"twenty":-20.815783,"median":-16.340404,"eighty":-14.242502,"marketCap":851834915},{"date":"2023-11-24","current":-12.473884,"twenty":-20.732342,"median":-15.9863,"eighty":-13.271633,"marketCap":871597891},{"date":"2023-12-01","current":-14.149156,"twenty":-20.643994,"median":-15.77974,"eighty":-12.959786,"marketCap":988655514},{"date":"2023-12-08","current":-15.76641,"twenty":-20.320051,"median":-15.713345,"eighty":-13.06857,"marketCap":1101659195},{"date":"2023-12-15","current":-16.854248,"twenty":-20.280785,"median":-15.705968,"eighty":-13.227243,"marketCap":1177670639},{"date":"2023-12-22","current":-18.52952,"twenty":-20.262175,"median":-15.76641,"eighty":-13.271633,"marketCap":1294728262},{"date":"2023-12-29","current":-21.77128,"twenty":-20.316166,"median":-15.824003,"eighty":-13.537135,"marketCap":1521242365},{"date":"2024-01-05","current":-20.48763,"twenty":-20.454114,"median":-15.9863,"eighty":-13.786432,"marketCap":1431548862},{"date":"2024-01-12","current":-23.098443,"twenty":-20.721111,"median":-16.285075,"eighty":-14.084509,"marketCap":1613976327},{"date":"2024-01-19","current":-23.34502,"twenty":-20.899222,"median":-16.57141,"eighty":-14.120082,"marketCap":1631205588},{"date":"2024-01-26","current":-26.1734,"twenty":-21.423171,"median":-16.854248,"eighty":-14.149156,"marketCap":1828835342},{"date":"2024-02-02","current":-24.650426,"twenty":-22.136094,"median":-16.901067,"eighty":-14.410237,"marketCap":1722419321},{"date":"2024-02-09","current":-26.833356,"twenty":-22.901778,"median":-17.107628,"eighty":-14.722084,"marketCap":1874948952},{"date":"2024-02-16","current":-25.919571,"twenty":-23.170966,"median":-17.443289,"eighty":-14.732183,"marketCap":1811099339},{"date":"2024-02-23","current":-25.462679,"twenty":-23.458155,"median":-17.594521,"eighty":-14.738085,"marketCap":1779174532},{"date":"2024-03-01","current":-25.252364,"twenty":-23.903055,"median":-18.011929,"eighty":-14.745463,"marketCap":1764478986},{"date":"2024-03-08","current":-39.349598,"twenty":-24.476372,"median":-18.248406,"eighty":-14.75284,"marketCap":3304775976},{"date":"2024-03-15","current":-39.31944,"twenty":-25.034796,"median":-18.52952,"eighty":-14.795627,"marketCap":3302243192},{"date":"2024-03-22","current":-40.133695,"twenty":-25.237859,"median":-19.967125,"eighty":-14.977105,"marketCap":3370628348},{"date":"2024-03-28","current":-41.080642,"twenty":-25.310382,"median":-20.039026,"eighty":-15.024319,"marketCap":3450157751},{"date":"2024-04-05","current":-35.585933,"twenty":-25.583066,"median":-20.203754,"eighty":-15.040549,"marketCap":2988684589},{"date":"2024-04-12","current":-40.39061,"twenty":-25.977589,"median":-20.297181,"eighty":-15.087984,"marketCap":3392205375},{"date":"2024-04-19","current":-33.647243,"twenty":-26.134238,"median":-20.48763,"eighty":-15.119386,"marketCap":2825863713},{"date":"2024-04-26","current":-30.802638,"twenty":-26.87687,"median":-20.704265,"eighty":-15.154157,"marketCap":2586959527},{"date":"2024-05-03","current":-35.061005,"twenty":-31.417884,"median":-20.865853,"eighty":-15.223502,"marketCap":2944598502},{"date":"2024-05-10","current":-35.544605,"twenty":-33.702281,"median":-21.144633,"eighty":-15.273667,"marketCap":2985213654},{"date":"2024-05-17","current":-30.341768,"twenty":-33.2059,"median":-21.423171,"eighty":-15.316454,"marketCap":3142011451},{"date":"2024-05-24","current":-25.989488,"twenty":-32.751748,"median":-21.791716,"eighty":-15.341537,"marketCap":2691315483},{"date":"2024-05-31","current":-26.170128,"twenty":-32.249341,"median":-22.218395,"eighty":-15.347905,"marketCap":2710021411},{"date":"2024-06-07","current":-23.773834,"twenty":-31.497141,"median":-22.764347,"eighty":-15.361417,"marketCap":2461875577},{"date":"2024-06-14","current":-24.341154,"twenty":-31.168024,"median":-22.917136,"eighty":-15.378422,"marketCap":2520623884},{"date":"2024-06-21","current":-21.479149,"twenty":-30.802638,"median":-22.901778,"eighty":-15.396128,"marketCap":2224251827},{"date":"2024-06-28","current":-22.551696,"twenty":-30.67474,"median":-22.901778,"eighty":-15.416784,"marketCap":2335318278},{"date":"2024-07-05","current":-21.168675,"twenty":-30.454668,"median":-22.551696,"eighty":-15.452028,"marketCap":2192101012},{"date":"2024-07-12","current":-25.927394,"twenty":-30.290963,"median":-22.599678,"eighty":-15.490824,"marketCap":2684885320},{"date":"2024-07-15","current":-27.107194,"twenty":-30.240158,"median":-22.64766,"eighty":-15.512581,"marketCap":2807058416},{"date":"2024-08-02","current":-25.825784,"twenty":-30.189354,"median":-22.706004,"eighty":-15.534337,"marketCap":2674363235},{"date":"2024-08-09","current":-22.78314,"twenty":-29.894686,"median":-22.901778,"eighty":-15.586554,"marketCap":2359285249},{"date":"2024-08-16","current":-22.360657,"twenty":-29.660984,"median":-22.773744,"eighty":-15.598555,"marketCap":2649402436},{"date":"2024-08-23","current":-23.604561,"twenty":-29.231009,"median":-22.862169,"eighty":-15.66023,"marketCap":2796786413},{"date":"2024-08-30","current":-24.399278,"twenty":-28.636347,"median":-22.994085,"eighty":-15.707443,"marketCap":2890948398},{"date":"2024-09-06","current":-23.811878,"twenty":-28.151516,"median":-23.098851,"eighty":-15.725149,"marketCap":2821350409},{"date":"2024-09-13","current":-24.28081,"twenty":-27.512504,"median":-23.170966,"eighty":-15.752276,"marketCap":2876911828},{"date":"2024-09-20","current":-26.136794,"twenty":-27.110581,"median":-23.268758,"eighty":-15.786496,"marketCap":3096818079},{"date":"2024-09-27","current":-28.649283,"twenty":-28.484417,"median":-23.34502,"eighty":-15.822528,"marketCap":3394510318},{"date":"2024-10-04","current":-28.061884,"twenty":-28.569318,"median":-23.434542,"eighty":-15.893348,"marketCap":3324912329},{"date":"2024-10-11","current":-26.610663,"twenty":-28.484417,"median":-23.533922,"eighty":-16.011479,"marketCap":3152964356},{"date":"2024-10-18","current":-27.755844,"twenty":-28.448831,"median":-23.612583,"eighty":-16.121447,"marketCap":3288651192},{"date":"2024-10-25","current":-25.643182,"twenty":-28.355515,"median":-23.773834,"eighty":-16.274009,"marketCap":3038332374},{"date":"2024-10-31","current":-27.099339,"twenty":-28.252419,"median":-23.811878,"eighty":-16.385155,"marketCap":3210865204},{"date":"2024-11-08","current":-28.654219,"twenty":-28.465143,"median":-23.860074,"eighty":-16.567059,"marketCap":3395095175},{"date":"2024-11-15","current":-19.789128,"twenty":-28.485404,"median":-23.853973,"eighty":-16.630879,"marketCap":2902332924},{"date":"2024-11-22","current":-16.628998,"twenty":-28.465143,"median":-23.803477,"eighty":-16.671147,"marketCap":2438858722},{"date":"2024-11-29","current":-17.517481,"twenty":-28.399895,"median":-23.76973,"eighty":-16.839744,"marketCap":2569166386},{"date":"2024-12-06","current":-18.297329,"twenty":-28.288946,"median":-23.604561,"eighty":-16.854248,"marketCap":2683541235},{"date":"2024-12-13","current":-17.195455,"twenty":-28.106309,"median":-23.497667,"eighty":-16.861788,"marketCap":2521936971},{"date":"2024-12-20","current":-18.243012,"twenty":-28.061884,"median":-23.417542,"eighty":-16.878936,"marketCap":2675574828},{"date":"2024-12-27","current":-18.305089,"twenty":-28.042139,"median":-23.34502,"eighty":-16.878936,"marketCap":2684679293},{"date":"2025-01-03","current":-18.29345,"twenty":-27.898004,"median":-23.314068,"eighty":-16.905494,"marketCap":2682972206},{"date":"2025-01-10","current":-19.092697,"twenty":-27.799282,"median":-23.175118,"eighty":-16.935003,"marketCap":2800192201},{"date":"2025-01-17","current":-14.239016,"twenty":-27.785817,"median":-23.13304,"eighty":-16.857264,"marketCap":2088336797},{"date":"2025-01-24","current":-15.60084,"twenty":-27.774326,"median":-23.084739,"eighty":-16.58873,"marketCap":2288066011},{"date":"2025-01-31","current":-16.489324,"twenty":-27.755844,"median":-22.901778,"eighty":-16.251878,"marketCap":2418373675},{"date":"2025-02-07","current":-16.155657,"twenty":-27.743997,"median":-22.822654,"eighty":-16.03771,"marketCap":2369437172},{"date":"2025-02-14","current":-14.068303,"twenty":-27.666994,"median":-22.64766,"eighty":-15.83959,"marketCap":2063299516},{"date":"2025-02-21","current":-13.17206,"twenty":-27.548527,"median":-22.532767,"eighty":-15.742854,"marketCap":1931853794},{"date":"2025-02-28","current":-11.845154,"twenty":-27.262231,"median":-22.345048,"eighty":-15.697836,"marketCap":1737245842},{"date":"2025-03-07","current":-11.30201,"twenty":-27.112839,"median":-22.212997,"eighty":-15.60472,"marketCap":2058615932},{"date":"2025-03-14","current":-12.223647,"twenty":-27.107194,"median":-21.977899,"eighty":-15.577851,"marketCap":2226488393},{"date":"2025-03-21","current":-12.874214,"twenty":-27.104275,"median":-21.832491,"eighty":-15.410728,"marketCap":2344986602},{"date":"2025-03-28","current":-12.51704,"twenty":-27.099339,"median":-21.774807,"eighty":-15.344488,"marketCap":2279928762},{"date":"2025-03-31","current":-12.666926,"twenty":-27.097365,"median":-21.77128,"eighty":-15.338586,"marketCap":2307229820}],"updateTime":1743505199290}}}